Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1.0%
- Check14 days agoChange DetectedDifference0.2%
- Check22 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.7%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check57 days agoChange DetectedThe page has removed a citation regarding the final analysis of KEYNOTE-170 related to Pembrolizumab in a specific type of lymphoma, which is a significant change in core content.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.